Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast, Advisory

Castle Biosciences to Present at the 24th Annual Needham Growth Conference


Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 24th Annual Needham Growth Conference on Monday, Jan. 10, 2022, at 12:30 p.m. Eastern time.

A live audio webcast of the company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that provides personalized, clinically actionable information to clinicians and patients to inform treatment decisions and improve health outcomes. The Company is focused on transforming the disease management paradigm in skin cancer and other diseases with high clinical need by leveraging advanced technologies for its portfolio of innovative diagnostic tests.

Castle's current portfolio consists of tests for skin cancers, uveal melanoma and Barrett's esophagus. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq and TissueCypher are trademarks of Castle Biosciences, Inc.


These press releases may also interest you

at 21:27
Labcorp Announces Winning Bid for Select Assets of Invitae
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:19
Invitae Enters into Agreement with Labcorp for Sale of Business
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
/C O R R E C T I O N -- Valcare Medical/
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...

at 21:02
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...

at 19:59
Genomma Lab Internacional Announces Results for the First Quarter 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...

at 19:46
South Florida City Launches Groundbreaking Initiative to Reduce Gun Violence and Foster Peace
Although gun violence is down by 12%, gun-related homicide is up by 44%. Therefore, the City of Lauderhill is announcing a pivotal strategy to reduce gun violence and promote peace among its 75,000 residents. This plan highlights Lauderhill's...

More news about Health...


News published on and distributed by: